Journal of Clinical Investigation Submission Guide: What to Prepare Before You Submit

Journal of Clinical Investigation is not a pure basic-science venue and not a pure clinical-outcomes venue. Editors are usually screening for:

• mechanistic explanation tied directly to disease
• enough human or disease relevance that the translational frame feels earned
• a package broad enough for physician-scientist readers
• a manuscript that already looks review-ready rather than promising but premature

That makes it a distinct target. The journal rewards the bridge between mechanism and disease, not either side alone.

JCI publishes Research Articles, Technical Advances, and Commentaries. Research Articles are the primary route for most authors.

Source: JCI author instructions, American Society for Clinical Investigation

Submission system is the JCI online portal at accounts.jci.org. There is no APC; JCI charges a publication fee of $5,800 upon acceptance (subscription model). A sex-as-biological-variable paragraph is mandatory in the Methods section. A Supporting Data Values Excel file is required for every figure that contains statistics.

Many weak JCI submissions are fit problems disguised as packaging problems. Research Articles work best when the manuscript makes one translational argument clearly: what disease problem matters, what mechanism explains it, and why the evidence package is strong enough to support that claim.

Before you worry about forms or file upload, ask:

• what disease mechanism does the paper actually resolve
• what part of the story depends on human or disease-facing evidence
• what is the first place an editor would say the claim is still too descriptive
• whether the paper would still fit Journal of Clinical Investigation if you removed the most ambitious translational language

If the answers are weak, the issue is fit, not formatting.

JCI's 60-70% desk-rejection rate reflects a focused editorial screen. Physician-scientist editors apply four questions on first read, each with a concrete pass condition.

The manuscript should make one translational argument, not several partial ones. The strongest packages usually have:

• a title that signals the disease context and the mechanistic move
• an abstract that makes the bridge visible early
• early figures that show the disease relevance and the mechanism working together
• a discussion that sounds translational without overpromising

The cover letter should:

• state the disease problem clearly
• state the mechanistic contribution clearly
• explain why those two pieces together make this a Journal of Clinical Investigation paper

Weak cover letters ask for prestige. Strong cover letters explain fit.

The first figures should make the bridge visible. If disease significance appears only late in the figure sequence or the human relevance looks like an appendix, the package weakens on first read. JCI editors evaluate whether the central translational argument is demonstrated in the opening figures, not just stated.

Before upload, the package should already look stable: the translational argument, figure order, and key controls are settled. Required elements include a Supporting Data Values Excel file for all figures containing statistics, a sex-as-biological-variable statement in the Methods section, and completed reporting checklists (CONSORT for trials, STROBE for observational studies). If these pieces are still unfinished, it is usually too early to submit.

• the disease layer is rhetorical instead of structural
• the human evidence is too light
• the mechanism is still mostly descriptive
• the translational claim outruns the figures
• the manuscript looks like two half-fit papers stitched together
• the package is still one revision cycle short of a hard editorial read

Those are not cosmetic misses. They are the real reasons the fit breaks.

Even good science often shows the mismatch in visible ways:

• the abstract sounds translational, but the figures still mainly describe patterns
• the human component is present, but it does not actually support the central claim
• the disease language is strong while the mechanism remains partial
• the paper reads like a basic paper with patient flavor rather than a true disease-mechanism bridge

That is why some respectable papers move better in a different venue.

Before anyone sends the paper to review, the package should already communicate:

• what disease mechanism is being resolved
• why the disease consequence matters
• why the human or disease-facing evidence changes the argument
• why the story belongs in Journal of Clinical Investigation rather than somewhere more basic or more clinical

If those points still require too much author explanation, the package usually is not yet doing enough work on its own.

• the paper is still mainly descriptive
• the disease relevance still feels argued rather than demonstrated
• the human layer is too light
• the mechanism still depends on one obvious missing step
• a more basic or more specialist journal still feels like the more honest home

• Is Journal of Clinical Investigation a Good Journal?
• How to Avoid Desk Rejection at Journal of Clinical Investigation
• Nature Medicine journal overview

Before you upload, run your manuscript through a JCI translational evidence and submission readiness check to catch the issues editors filter for on first read.

In our pre-submission review work with manuscripts targeting the Journal of Clinical Investigation, three patterns generate the most consistent desk rejections among the papers we analyze.

In our experience, roughly 35% of desk rejections at the Journal of Clinical Investigation trace to scope or framing problems that prevent the paper from competing in this venue. In our experience, roughly 25% involve insufficient methodological rigor or missing validation evidence. In our experience, roughly 20% arise from a novelty claim that outpaces the supporting data.

• Disease relevance that lives only in the Introduction and Discussion, not in the data. JCI's author instructions emphasize that accepted papers must demonstrate "mechanistic understanding of disease processes relevant to human biology," and we see a recurring pattern where the experimental data are strong basic science but the disease connection appears only in framing language. Editors can identify this immediately: if removing every sentence that mentions the disease name would not change what the figures show, the translational argument has not been built into the paper.

• Mechanistic claims that read as correlational rather than causal. JCI editors want to see that the mechanism is tested, not just observed. We observe that papers presenting association-level evidence, genetic correlations, or expression patterns without functional validation of the proposed mechanism, consistently draw either desk rejection or a first-round revision request that cannot be addressed without substantial new experiments. Papers that include loss-of-function or gain-of-function data, genetic rescue experiments, or human disease variant validation survive the screen at a much higher rate.

• Human evidence added as a final panel rather than built into the argument. JCI's scope requires work that is relevant to human disease, and we observe that human data positioned as confirmatory, a single patient cohort at the end of an otherwise mouse-model paper, consistently weakens the submission even when the human data are significant. The papers that clear the editorial screen are those where the human evidence changes how the mechanism is framed, not just where it is mentioned.

SciRev author-reported data confirms JCI's approximately 45-day median to first decision for papers that pass desk review. A JCI mechanistic evidence and human disease framing check can assess whether your mechanistic evidence and human disease framing meet the journal's translational standard before you submit.